相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Medicine, General & Internal
Wen Wen et al.
Summary: This study conducted a meta-analysis on three new oral antivirals (molnupiravir, fluvoxamine, and Paxlovid) and their effects on mortality and hospitalization rates among COVID-19 patients. The results showed that these drugs were effective in reducing mortality and hospitalization rates by approximately 67%. Furthermore, the drugs did not increase adverse events, indicating good overall safety.
ANNALS OF MEDICINE
(2022)
Article
Medicine, General & Internal
Arabella S. Stuart et al.
Summary: The study investigated the mixed use of different COVID-19 vaccines within the same schedule, showing that in certain conditions, heterologous vaccination can achieve similar immunogenicity to homologous vaccination, facilitating rapid global vaccine deployment.
Article
Allergy
Leanne P. M. van Leeuwen et al.
Summary: This study evaluated the immune response of COVID-19 vaccines in patients with IEI. The results showed that COVID-19 vaccination was immunogenic in patients with mild antibody deficiencies and phagocyte defects, but had lower immunogenicity in patients with more severe IEI like CVID and combined B- and T-cell immunodeficiency. The presence of noninfectious complications and the use of immunosuppressive drugs negatively affected the antibody response in patients with CVID.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Article
Immunology
Adrian M. Shields et al.
Summary: SARS-CoV-2 vaccines show reduced immunogenicity in patients with antibody deficiency, with evidence of vaccine breakthrough infections.
JOURNAL OF CLINICAL IMMUNOLOGY
(2022)
Article
Immunology
Arnau Antoli et al.
Summary: The study found that SARS-CoV-2 vaccines are less effective in CVID phenotype and BCD patients compared to healthy individuals. Predictive factors of inadequate specific antibody response in CVID phenotype patients include low IgA values, low CD19+ peripheral B cells, low switched memory B cells, and a low CD4+/CD8+ ratio. Further studies are needed to understand the effectiveness of vaccines in immunocompromised patients and predictive factors of immune response failure.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Gerardo Cazzato et al.
Summary: This article discusses a case of multiple flat warts onset over the cheeks in a patient after receiving the BioNTech-Pfizer BNT162b2 vaccine, and explores the potential temporal association between vaccine administration and the patient's antibody status.
Article
Immunology
Adrian M. Shields et al.
Summary: Third primary immunizations can enhance humoral immunity against SARS-CoV-2 in individuals with antibody deficiency.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Rheumatology
Matthias B. Moor et al.
Summary: The study investigated immune responses to SARS-CoV-2 mRNA vaccines in patients receiving CD20-targeted B-cell-depleting therapies. Results showed blunted immune responses in these patients, indicating potential challenges in vaccination strategies for this population.
LANCET RHEUMATOLOGY
(2021)
Article
Allergy
Isabelle Meyts et al.
Summary: The study shows that patients with IEI exhibit varied responses to SARS-CoV-2 infection, with some requiring hospitalization and even intensive care, and a non-negligible mortality rate. In comparison to the general population, younger IEI patients may face a higher risk of severe illness and mortality.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Article
Allergy
Adrian M. Shields et al.
Summary: Patients with PID and symptomatic SID have higher morbidity and mortality risks from COVID-19 compared to the general population, requiring enhanced protective measures.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Review
Public, Environmental & Occupational Health
Nicoletta Luxi et al.
Summary: While the benefit-risk profile of the four authorized COVID-19 vaccines has been largely favorable in the general population, evidence remains limited for special cohorts such as pregnant women, children, immunocompromised individuals, and those with a history of allergies or previous SARS-CoV-2 infection. This narrative review critically examines the potential benefits and risks of COVID-19 vaccines in these special cohorts, and summarizes recommendations from scientific societies and regulatory agencies for primary prevention in these vaccinee categories.
Article
Oncology
Livio Pagano et al.
Summary: This study analyzed baseline characteristics and predictors of mortality in hematological malignancy patients with COVID-19. Results showed that a high percentage of patients developed severe/critical symptoms, with a mortality rate of 31.2%, although improved prevention measures have decreased mortality rates despite an increase in reported cases.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Letter
Rheumatology
Michael Markus Bonelli et al.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Immunology
Donato Amodio et al.
Summary: The study analyzed the immune response following the BNT162b2 mRNA COVID-19 vaccine in immunocompromised patients compared to healthy controls. It found that some immunocompromised patients did not develop specific CD4+CD40L+ T cell responses, indicating the importance of evaluating T cell immune responses in this subpopulation.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Cheng-Lung Ku et al.
Summary: Inborn errors of immunity (IEIs) are genetically defined disorders that may lead to defective immunity. Some IEIs are linked to mutations of immune receptors or signaling molecules. In cases of COVID-19, IEIs have been associated with increased inflammation in some patients, and targeting inflammation may be a potential therapeutic approach for these diseases.
Review
Endocrinology & Metabolism
Awadhesh Kumar Singh et al.
Summary: Molnupiravir has shown significant benefits in reducing hospitalization or death in mild COVID-19 cases, making it a potential important tool in combating SARSCoV-2. However, its efficacy in moderate to severe COVID-19 remains uncertain, requiring further studies for clarification.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
(2021)
Letter
Allergy
Cinzia Milito et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2021)
Article
Rheumatology
Victoria Furer et al.
Summary: Vaccination with mRNA BNT162b2 vaccine showed reduced immunogenicity in patients with AIIRD compared to the general population, with risk factors including older age and treatment with glucocorticoids, rituximab, mycophenolate mofetil (MMF), and abatacept. However, most patients maintained stable disease activity post-vaccination.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Allergy
David Hagin et al.
Summary: The study evaluated the humoral and cellular immune response to the COVID-19 vaccine in patients with IEI, finding that most patients were able to develop vaccine-specific antibody response and S-protein-specific cellular response, and no significant adverse events were reported during the vaccination process.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Article
Allergy
Ottavia M. Delmonte et al.
Summary: The study evaluated antibody response and adverse events in IEI patients after COVID-19 vaccination, finding that vaccination is safe but immunogenicity is affected by certain therapies and gene defects. This data can guide counseling of IEI patients on preventing SARS-CoV-2 infection and the need for subsequent boosts.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Article
Immunology
Ekaterini Simoes Goudouris et al.
Summary: The study found that most patients with IEI had mild symptoms of SARS-CoV-2 infection, but the Case Fatality Ratio was higher than in the general population. The type of IEI was not a determining factor for severity, but older age, a higher number of comorbidities (especially bronchiectasis and cardiopathy) were related to increased severity of infection.
JOURNAL OF CLINICAL IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Dami A. Collier et al.
Summary: Elderly individuals, especially those above eighty, show lower immune responses and neutralization abilities against variants of concern after the first vaccine dose, but this improves after the second dose. They have higher frequencies of spike-specific memory B cells but reduced somatic hypermutation of class-switched cells. Production of interferon-gamma and interleukin-2 by SARS-CoV-2 spike-specific T cells is lower in older participants, predominantly by CD4 T cells.
Review
Infectious Diseases
Musha Chen et al.
Summary: A systematic review and meta-analysis found that the safety and tolerance of current COVID-19 vaccine candidates are acceptable for mass vaccination, with inactivated COVID-19 vaccines candidates having the lowest reported adverse events following immunization (AEFI). Long-term surveillance of vaccine safety is required, especially among elderly people with underlying medical conditions.
INFECTIOUS DISEASES OF POVERTY
(2021)
Review
Allergy
Matthew Greenhawt et al.
Summary: This study involved an international multidisciplinary group of experts to systematically investigate the incidence of anaphylaxis after SARS-CoV-2 vaccination and the accuracy of allergy testing tools. The research found a low incidence of anaphylaxis after SARS-CoV-2 vaccination and low sensitivity of polyethylene glycol skin testing, but high specificity. Recommendations were made for vaccination for individuals without a history of severe allergic reactions and shared decision-making with an allergy specialist for those with a history of severe allergic reactions. Further research is recommended to clarify the utility of testing in individuals potentially allergic to SARS-CoV-2 vaccines or their excipients.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2021)
Article
Allergy
Markus G. Seidel et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2019)
Article
Allergy
Elena Blanco et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2018)
